Li Lanjuan (1947.9-) is a female from Xialuqiao Village, Lvxia Town, Shaoxing County, Zhejiang Province. Han nationality, infectious disease expert, academician of China Academy of Engineering, leader of national key infectious diseases discipline, director of Key Laboratory of Infectious Diseases of Ministry of Health, pioneer of artificial liver in China, former director of Health Department of Zhejiang Province, director, professor, chief physician and doctoral supervisor of Key Laboratory of Infectious Diseases of Ministry of Health, executive director of China Women Medical Association, director of Chinese Medical Association, president of Zhejiang Branch of Chinese Medical Association, deputy director of Infectious Diseases Branch of Chinese Medical Association, deputy director of Microecology Branch of Chinese Preventive Medical Association, and liver failure and artificial. Editor-in-chief of Infectious Diseases, a textbook for medical planning in national colleges and universities, editor-in-chief of Infectious Diseases magazine, and deputy editor-in-chief of Infectious Diseases in China and Foreign Medical Epidemiology. Director of National Artificial Liver Training Base. In 2005, he was elected as an academician of China Academy of Engineering.

Li Lanjuan graduated from the Faculty of Medicine of Zhejiang Medical University from 65438 to 0973, and has been engaged in the medical treatment, teaching and research of infectious diseases for more than 30 years with remarkable achievements. From March, 2065438 to March, 2003, China scientists led by Academician Li Lanjuan made a major breakthrough in the research of H7N9 avian influenza. The paper "Human Infected with New H7N9 Avian Influenza Virus from Live Birds Market: Clinical Analysis and Genomic Characteristics of the Virus" has been published online in The Lancet, a world-renowned medical journal.

A major breakthrough (ALSS) has been made in establishing a unique and effective artificial liver support system to treat severe hepatitis. The mortality of acute and subacute severe liver diseases decreased significantly from 88. 1% to 2 1. 1%, and the mortality of chronic severe liver diseases decreased from 84.6% to 56.6%. More than 700 cases have been treated. Presided over the formulation of ALSS technical specifications as national standards and actively promoted them to the whole country; Won the second prize of national scientific and technological progress. Establish the first immortalized human-derived hepatocyte line in China; Create a new method of four-step perfusion separation of hepatocytes; Construction of a new hybrid artificial liver. Nine patents have been applied and two have been authorized. The change law of intestinal microecology with severe liver disease was revealed for the first time, and the B/E value was put forward as a new index of intestinal colonization resistance. Five new β -lactamase genotypes were discovered and won the first prize of provincial scientific and technological progress in 0 1 and 03 respectively. Published more than 30 papers 10, and SCI included more than 0 papers10. Editor-in-chief: 8 monographs and 9 monographs.